Crossmark

Synergistic overcoming of cisplatin resistance in ovarian cancer by combined Astragalus Membranaceus and cisplatin treatment: network pharmacology and experimental validation

Crossref DOI link: https://doi.org/10.1186/s12906-025-05066-8

Published Online: 2025-09-30

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Fei

Yue, Qing-fang

Zhang, Yu

Lei, Fang-liang
Funding

Funding for this research was provided by:

Natural Science Foundation of Shaanxi Province (2021JQ-912)

Shaanxi Provincial People’s Hospital Talent Support Program (2022JY-13)
License Information

Text and Data Mining valid from 2025-09-30

Version of Record valid from 2025-09-30
More Information

Article History

Received: 14 August 2024

Accepted: 30 July 2025

First Online: 30 September 2025

Declarations

:

: The study was conducted in accordance with the Declaration of Helsinki, and the Shaanxi Provincial People’s Hospital Medical Ethics Committee approved it (approval code: 2023 K-S069).

: The authors declare no competing interests.

Document is current

Any future updates will be listed below